Donaldson Company has acquired Univercells Technologies, a producer of innovative biomanufacturing solutions for cell and gene therapy research, development and commercial manufacturing.
Univercells Technologies’ product offering includes the unique scale-X single-use structured fixed-bed bioreactor for the intensified production of viruses used in cell and gene therapy, viral vaccines and other therapeutics. In addition, the Company’s automated NevoLine Upstream platform incorporates industry-standard filtration to provide integrated up- and mid-stream processing capabilities in a single unit driving productivity improvements, reduced operational footprints and greater consistency of results.
We are extremely excited to join Donaldson as we grow our portfolio of best-in-class biomanufacturing platforms
“The acquisition of Univercells Technologies represents an important next step in Donaldson’s life sciences strategy, as we continue to expand our product portfolio aimed at providing customers with a comprehensive, differentiated offering,” said Tod Carpenter, chairman and CEO of Donaldson. “Univercells Technologies’ engineered systems provide close adjacencies with our previous life sciences acquisitions as well as with our growing organic product suite.”
“We are extremely excited to join Donaldson as we grow our portfolio of best-in-class biomanufacturing platforms and increase our market penetration and related installed base of equipment," said Mathias Garny, CEO of Univercells Technologies. “Our tech, complemented by Donaldson’s filtration excellence and existing life sciences capabilities is part of a larger vision to bring end-to-end solutions to market for advanced therapies.”
Headquartered in Nivelles, Belgium, Univercells Technologies has over 100 employees globally. The company generated approximately €10 million of revenue in calendar 2022 and was acquired for cash consideration of €136 million on a cash-free, debt-free basis and subject to closing adjustments. Univercells Technologies is being acquired from Gamma Biosciences and Univercells SA and will be a part of the Donaldson Life Sciences segment. Baker McKenzie acted as legal advisors to Donaldson.